Pharvaris Statistics
Total Valuation
Pharvaris has a market cap or net worth of $1.75 billion. The enterprise value is $1.37 billion.
Important Dates
The last earnings date was Wednesday, November 12, 2025, before market open.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharvaris has 72.31 million shares outstanding. The number of shares has increased by 9.08% in one year.
| Current Share Class | 72.31M |
| Shares Outstanding | 72.31M |
| Shares Change (YoY) | +9.08% |
| Shares Change (QoQ) | +13.18% |
| Owned by Insiders (%) | 4.71% |
| Owned by Institutions (%) | 40.28% |
| Float | 49.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.10 |
| P/TBV Ratio | 4.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.86, with a Debt / Equity ratio of 0.00.
| Current Ratio | 12.86 |
| Quick Ratio | 12.67 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -53.76% and return on invested capital (ROIC) is -34.30%.
| Return on Equity (ROE) | -53.76% |
| Return on Assets (ROA) | -32.07% |
| Return on Invested Capital (ROIC) | -34.30% |
| Return on Capital Employed (ROCE) | -53.51% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.78M |
| Employee Count | 108 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Pharvaris has paid $1.83 million in taxes.
| Income Tax | 1.83M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +22.28% in the last 52 weeks. The beta is -2.78, so Pharvaris's price volatility has been lower than the market average.
| Beta (5Y) | -2.78 |
| 52-Week Price Change | +22.28% |
| 50-Day Moving Average | 23.19 |
| 200-Day Moving Average | 19.16 |
| Relative Strength Index (RSI) | 57.42 |
| Average Volume (20 Days) | 203,553 |
Short Selling Information
The latest short interest is 531,875, so 0.74% of the outstanding shares have been sold short.
| Short Interest | 531,875 |
| Short Previous Month | 544,623 |
| Short % of Shares Out | 0.74% |
| Short % of Float | 1.09% |
| Short Ratio (days to cover) | 2.30 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -196.31M |
| Pretax Income | -190.26M |
| Net Income | -192.09M |
| EBITDA | -196.04M |
| EBIT | -196.31M |
| Earnings Per Share (EPS) | -$3.41 |
Full Income Statement Balance Sheet
The company has $386.35 million in cash and $678,936 in debt, giving a net cash position of $385.67 million or $5.33 per share.
| Cash & Cash Equivalents | 386.35M |
| Total Debt | 678,936 |
| Net Cash | 385.67M |
| Net Cash Per Share | $5.33 |
| Equity (Book Value) | 366.35M |
| Book Value Per Share | 5.92 |
| Working Capital | 364.86M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$157.31 million and capital expenditures -$380,145, giving a free cash flow of -$156.34 million.
| Operating Cash Flow | -157.31M |
| Capital Expenditures | -380,145 |
| Free Cash Flow | -156.34M |
| FCF Per Share | -$2.16 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Pharvaris does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.08% |
| Shareholder Yield | -9.08% |
| Earnings Yield | -10.95% |
| FCF Yield | -8.91% |
Analyst Forecast
The average price target for Pharvaris is $37.00, which is 52.51% higher than the current price. The consensus rating is "Buy".
| Price Target | $37.00 |
| Price Target Difference | 52.51% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |